Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine as Maintenance After Stem Cell Transplantation in AML or MDS
NCT04173533Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2019
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (2 arms), sponsored by University of Birmingham. Primary endpoint: Relapse-Free Survival at 12 months. Started Jun 2019; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT04173533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173533.